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Summary
Susceptibility to transmissible spongiform encephalopathies (TSEs) is strongly associated with PrP polymorphisms in humans, sheep and rodents. In mice, scrapie incubation time is controlled by polymorphisms at PrP codons 108 (leucine to phenylalanine) and 189 (threonine to valine), but the precise role of each polymorphism in the control of disease is unknown. The L108F and T189V polymorphisms are present in distinct structural regions of PrP, and thus provide an excellent model with which to investigate the role of PrP structure and gene variation in TSEs.  We have produced two unique lines of transgenic mice in which 108F and 189V have been targeted separately into the endogenous murine Prnpa gene.  TSE inoculation of inbred lines of mice expressing all allelic combinations at codons 108 and 189 has revealed a complex relationship between PrP allele and incubation time.  We have established that both codons 108 and 189 control TSE incubation time, and that each polymorphism plays a distinct role in the disease process.  Comparison of ME7 incubation times in mouse lines heterozygous at both codons has also identified a previously unrecognised intramolecular interaction between PrP codons 108 and 189.  

Introduction
The transmissible spongiform encephalopathies (TSEs) are a group of fatal, neurodegenerative diseases that include scrapie in sheep, Bovine Spongiform Encephalopathy (BSE) in cattle, Chronic Wasting Disease (CWD) in deer and elk, and Creutzfeldt Jakob Disease (CJD), Gerstmann Straussler Scheinker (GSS) disease, and Fatal Familial Insomnia (FFI) in man. TSE diseases are thought to be caused by conversion of a normal cellular glycoprotein (PrPC) into an abnormal disease associated isoform (PrPSc) which accumulates in diseased tissue (Prusiner, 1996). This conversion of PrPC to PrPSc is accompanied by an alteration in conformation from predominantly alpha-helix to beta-sheet structure and development of partial resistance to digestion with proteinase K (PK).  It has been proposed that PrPSc constitutes infectivity (Prusiner, 1982) and acts as a seed or a template in the conversion of host PrPC to PrPSc (Jarrett & Lansbury, 1993; Prusiner, 1996; Weissmann, 1996).  Whether PrPSc is indeed the infectious agent, remains to be established, but the conversion of PrPC to PrPSc is clearly a critical event in the pathogenesis of these diseases. 

The host PrP gene (Prnp) has a major influence over the outcome of TSE disease. PrP polymorphisms have been shown to alter incubation time and TSE susceptibility in mice (Moore et al., 1998), sheep (Goldmann et al., 1994) and man (Palmer et al., 1991; Goldfarb et al., 1992).   Classical genetic analysis of the control of TSE incubation time in mice identified the presence of a single gene (Sinc) encoding two alleles (s7 and p7) which programmed short and long incubation times respectively for the ME7 strain of scrapie (Dickinson et al., 1968). Similar differences in incubation times have been found between NZW/LacJ and Iln/J mouse strains when infected with the Chandler isolate, identifying a single locus Prni controlling incubation time, which was closely linked to Prnp (Carlson et al., 1986).  Following isolation and characterisation of the gene encoding PrP in mice (Prnp) (Basler et al., 1986; Locht et al., 1986) mouse strains carrying Sinc s7 were shown to have a Prnp gene encoding 108L_189T (Prnpa) and those carrying Sinc p7 had a Prnp gene encoding 108F_189V (Prnpb) (Westaway et al., 1987).  However, due to the different genetic backgrounds of these lines of inbred mice it was difficult to confirm that the Prnp, Sinc and Prni genes were congruent, and that the polymorphisms in Prnp were responsible for the control of scrapie incubation time in mice. 

The introduction of 108F and 189T into the murine Prnpa gene by gene targeting produced a line of transgenic mice (FV/FV) which differed from the 129/Ola parental line by only the targeted polymorphisms.  Inoculation of these mice with TSE infectivity produced incubation times similar to Prnpb mice, demonstrating that Sinc, Prni and Prnp were indeed the same gene, and that the codon 108 and/or codon 189 polymorphisms were the major factor controlling TSE incubation time in mice (Moore et al., 1998; Barron et al., 2003; Barron & Manson, 2004). 

In order to determine the individual involvement of the 108 and 189 polymorphisms in disease, and the mechanism by which they control TSE incubation time in mice, 108F and 189V have been introduced separately into the murine Prnpa gene by gene targeting. These new alleles are designated Prnpa[108L_189V]   (PrnpLV ) and Prnpa[108F_189T] (PrnpFT). Inoculation of mice homozygous for Prnpa, Prnpb, PrnpLV or PrnpFT  and their heterozygous crosses with mouse scrapie have demonstrated the involvement of both polymorphisms in the control of incubation time.  

Methods
Production of targeting vectors.  
An 8,524bp 129/Ola Prnpa genomic DNA clone spanning PrP exon 3 was isolated from a  DASH II 129/Ola HM-1 ES cell genomic DNA library and cloned into pBluescript II. The wild-type PrP ORF encoding Prnpa  (108L_189T) was modified using in vitro mutagenesis to express 108F or 189V alone, rather than both, as described (Moore et al., 1998). Vectors p108F and p189V were modified to introduce an HSV-TK module and a LoxP flanked PGK/HPRT minigene downstream of exon 3 for selection (Figure 1).  This resulted in the generation of 15.7Kb constructs p108F_LoxP/HPRT/TK and p189V_LoxP/HPRT/TK showing 6.4Kb of 5’ homology and 1.4 Kb of 3’ homology flanking the LoxP/HPRT minigene. The LoxP flanked HPRT minigene was derived from pBTLoxP_HPRTv2 and consists of a PGK driven HPRT minigene (Selfridge et al., 1992) in pBTSKII+ flanked by two 38bp LoxP sites, allowing the Cre mediated excision of the LoxP flanked HPRT minigene. 


Generation of ES lines and mice with PrP codon 108 and 189 alterations. 
For each experiment, 200µg of p108F_LoxP/HPRT/TK or p189V_LoxP/HPRT/TK was linearised by digestion with Not I and electroporated into HM-1 ES cells (50 x 106 cells, 900V, 3µFd). All tissue culture reagents and conditions were as described previously (Thompson et al., 1989; Selfridge et al., 1992; Moore & Melton, 1995). ES cells surviving HAT and gancyclovir drug selection were screened for homologous recombination events by PCR with primer pair 262W (5′-AGCCTACCCTCTGGTAGATTGTCG-3′) and W6991(5′- CCCAATTCTCTCCTTCTAAGGGAG -3′) to amplify the HPRT minigene, [940C (60s), 660C (60s), 720C (95s); 35 cycles]. Targeted clones amplified a 1.75Kb targeting-specific band, and were further screened for the PrP codon 108 or 189 alterations by a combination of PCR and restriction digestion. The PrP ORF was amplified with primers A996 (5′-GTGGCTGGGGACAACCCCAT-3′) and B188 (5′- GCCTAGACCACGAGAATGCG -3′) to generate a 624bp PCR product [940C (30s), 650C (30s), 720C (60 s); 35 cycles]. The codon 108 alteration was detected by the loss of a Mnl I site following the single nucleotide change (CTC to TTC).  Codon 189 alteration was detected by digestion with BstE II as described previously (Moore & Melton, 1995).  

Cre-deletion of the HPRT minigene. 
The LoxP-flanked PGK/HPRT module was excised from targeted alleles by transient transfection of ES cells with Cre recombinase expression construct, pMCCreN (Gu et al., 1993). Clones were transfected with 150µg of pMCCreN (10 x 106 cells, 900V, 3µFd) and selected by 6-thioguanine. Drug resistant clones were screened for deletion of the LoxP-flanked HPRT minigene by PCR with primers W7878 (5′- AGTCAGGGAGGAGTAACACAGAAGG -3′) and W6991 [940C (60s), 660C (60s), 720C (95s); 35 cycles]. This generated a 1.61Kb product from the wild type allele and a slightly larger band of 1.66Kb from the HPRT deletant allele. This size difference arises from the retention of a single 38bp LoxP site and a portion of the pBluescript multiple cloning site.  ES cell clones were examined by Southern analysis for the expected gene structure and the absence of additional recombination events, as described previously (Moore et al., 1995).

Generation of mice. 
Germline chimeras were generated as described (Thompson et al., 1989).  Briefly, HM-1 ES cells with the desired alterations were introduced into BALB/c 3.5-day blastocysts and transferred to pseudopregnant MF1 recipients. Chimeras were crossed directly to 129/Ola stock generating mice with PrP codon 108 and 189 alterations which were co-isogenic with the parental strain 129/Ola Hsd (Harlan, UK). Germline pups were screened by a combination of PCR and Mnl I or BstE II restriction digestion as described above. 129/Ola littermates heterozygous for the targeted PrP allele which were also wild type at the deleted HPRT locus in HM-1 cells were crossed to establish the line. 

Northern blot analysis.   
Total RNA was isolated from terminal brains using RNAzolTM B, based on the guanidinium thiocyanate phenol-chloroform extraction method (Chomczynski & Sacchi, 1987). Total RNA (50 µg) was separated on a 1.0% agarose-formaldehyde denaturing gel and transferred to Hybond N (Amersham Pharmacia Biotech, UK) by capillary transfer overnight. RNA was fixed to the membrane by baking at 80oC for 2 h before probing. A 936bp Kpn I - Eco RI fragment from Prnp exon 3 was used to generate the PrP probe.  Membranes were hybridised overnight using ULTRAhyb (Ambion). As a loading control, membranes were reprobed for 18s rRNA using a 275bp PCR generated murine DNA fragment. 

Western blot analysis. 
Homogenates of frozen brain tissue (10% w/v) were prepared in NP40 buffer [0.5% (v/v) NP40, 0.5% (w/v) sodium deoxycholate, 150 mM NaCl, 50 mM Tris/HCl pH 7.5].  Clarified homogenates (10,000 g for 10 min at 10oC) were incubated with or without Proteinase K (20 g/ml) for 1 hour at 37oC, and the reaction terminated by the addition of PMSF to 1mM.  Samples were prepared at 10 mg/ml concentration in SDS PAGE sample buffer (Novex, Invitrogen), incubated at 90oC for 20 min, and separated on 12% or 4 – 12 % Novex Tris-Glycine acrylamide gels (Invitrogen).  Proteins were transferred onto PVDF membrane by electroblotting, and incubated overnight at room temperature with mouse anti-PrP monoclonal antibody 7A12 (Li et al., 2000) at a dilution of 50ng/ml, or rat anti-tubulin monoclonal (Abcam) at 250ng/ml.  Proteins were visualised with horseradish peroxidase (HRP) conjugated anti-mouse or anti-rat secondary antibody diluted to 200ng/ml (Jacksons) and a chemiluminescence detection kit (Roche Diagnostics).  Membranes were exposed to X-ray film for periods ranging from 10 seconds to 10 minutes.

Preparation of inoculum. 
 Inocula were prepared from the brains of C57BL mice with terminal ME7 scrapie and the brains of VM mice with terminal 301V disease.  A 1% homogenate of each sample was prepared in sterile saline prior to use as an inoculum. All mice were inoculated intracerebrally with 20l of inoculum under anaesthesia.  All experimental protocols were submitted to the Local Ethical Review Committee for approval before mice were inoculated.  All experiments were performed under licence and in accordance with the UK Home Office Regulations (Animals (Scientific Procedures) Act 1986).

Scoring of clinical TSE disease. 
The presence of clinical TSE disease was assessed as described previously (Dickinson et al., 1968). Animals were scored for clinical disease without reference to the genotype of the mouse.  Genotypes were confirmed for each animal by PCR analysis of tail DNA at the end of the experiment. Incubation times were calculated as the interval between inoculation and cull due to terminal TSE disease. Mice were killed by cervical dislocation at the terminal stage of disease, at termination of the experiment (between 600-700 days), or for welfare reasons due to intercurrent illness.  Half-brains were fixed in 10% formal saline for 48h, followed by decontamination in 98% formic acid for 1h.  The remaining half-brain was frozen at -70oC for biochemical analysis.  Fixed brain tissue was dehydrated in alcohol and impregnated in wax during a 7h automated processing cycle.  Sections were cut coronally at 4 levels and mounted on Superfrost slides.

Lesion profiles.  
Sections were haematoxylin & eosin stained and scored for vacuolar degeneration on a scale of 0-5 in nine standard grey matter areas and three standard white matter areas as described previously (Fraser & Dickinson, 1967).

Genotyping of mouse-tail DNA. 
A 2-3cm portion of tail was removed post-mortem from each mouse. DNA was prepared from a 1cm piece of tail by digestion overnight at 370C  in tail lysis buffer (300mM Sodium acetate, 1% SDS, 10mM Tris pH 8, 1mM EDTA, 200µg/ml proteinase K) and subsequent extraction with an equal volume of phenol/chloroform.  DNA was precipitated with isopropanol, washed with 70% ethanol and resuspended in 100µl of TE buffer (10mM Tris, 1mM EDTA pH 7.4). A 605-bp PCR fragment for the Prnp ORF was generated from purified tail DNA with an ORF primer PrP5’> (5’-GTGGCTGGGGACAACCCCAT-3’) and an exon-3 3’-UTR primer PrP3’< (5’-GCCTAGACCACGAGAATGCG-3’). Cycle conditions were: 35 cycles, 94oC (30s), 65oC (30s), 72oC (1min). The PrnpLV allele, was detected by the absence of a BstE II site within this product compared with the wild type Prnpa allele. The PrnpFT allele, was detected by the absence of a Mnl I site compared with the wild type Prnpa allele.  

Results
Construction of the mouse lines
108F and 189V were introduced separately into the Prnpa allele of 129/Ola derived HM-1 embryonic stem (ES) cells, using a cre-lox gene targeting strategy (Lakso et al., 1992; Gu et al., 1993).  These targeting events produced ES cell clones expressing Prnpa[108F_189T] (PrnpFT) and Prnpa[108L_189V]  (PrnpLV) respectively.  Presence of the targeted mutations was verified by the loss of an Mnl I restriction site at codon 108 (CTC to TTC alteration), and the loss of a BstE II restriction site at codon 189 (ACC to GTC alteration) (Figure 1).  Southern blot analysis using probes derived from the intron/exon 2 region, from intron 2 and from exon 3 confirmed that no further alterations had occurred in the mouse genome during targeting (data not shown). DNA sequence analysis was carried out to ensure that the PrnpFT and PrnpLV alleles had undergone no detectable deletions, insertions or other rearrangements during the targeting process. However, the gene targeting strategy resulted in the retention of a 38 bp LoxP site and a small portion of pBluescript multiple cloning site (~100 bp) 2 kb downstream of the exon 3 of the Prnp gene (Figure 1).  The LoxP site was distant from the intergenic exons between Prnp and the closely located Prnd (doppel), and thus not expected to influence the expression of either gene.

HM-1 ES cell clones bearing the targeted PrnpFT or PrnpLV alleles were injected into 3.5-day old BALB/c blastocysts to create chimeric mice (Moore et al., 1995), which were crossed with 129/Ola mice to establish the FT/FT and LV/LV transgenic lines co-isogenic with 129/Ola.  The identical genetic background of the lines ensured that any observed alterations in incubation time and disease pathology were a direct result of the targeted mutations, and not due to the effects of genes from mice of other genetic backgrounds. 

Expression of PrP in the gene targeted lines
The expression levels of Prnp mRNA and mature PrPC were investigated in FT/FT and LV/LV brain, and compared with those in wild type 129/Ola mice (LT/LT) and the existing gene targeted transgenic line expressing Prnpa[108F_189V] (FV/FV) (Moore et al., 1998).  Northern blot (Figure 2) and western blot analysis (Figure 3) of tissues from each line confirmed expression from the PrnpFT and PrnpLV alleles, and indicated that the levels of expression in the three homozygous lines (FV/FV, LV/LV and FT/FT) were indistinguishable from wild type 129/Ola mice.  Prnp gene expression was therefore not affected by either the process of gene targeting, the introduction of the single polymorphism, or the presence of the LoxP site 3’ of the Prnp gene. Thus any alteration in incubation time and neuropathology observed on inoculation of these animals with TSE infectivity should be attributable to the specific alterations at codons 108 and 189, and not due to any differences in Prnp gene expression levels.

Interactions between  codon 108 and 189 polymorphisms and ME7 scrapie.
The ME7 strain of mouse scrapie is passaged in mice homozygous for the Prnpa gene (LT/LT), and produces short incubation times in Prnpa (LT/LT) mice, and prolonged incubation times in Prnpb (FV/FV) mice. Following ME7 challenge, LT/FV mice had incubation times of 223 days intermediate between parental lines LT/LT (155 days) and the gene targeted FV/FV (295 days). This pattern of allelic interaction recapitulates that observed between wildtype Prnpa, Prnpb and F1 crosses, and demonstrates that the gene targeted FV allele can reproduce the dominance-pattern observed in mice with wild type PrP alleles.  Incubation times of 168 days and 261 days were obtained in FT/FT and LV/LV lines of mice respectively (Table I) which were distinct from those in wild type LT/LT and gene targeted FV/FV mice, indicating that neither 108F nor 189T is solely responsible for the increased incubation time in FV/FV mice.  The most significant change in incubation time was due to the T to V alteration at codon 189, producing a ~100 day difference between LT/LT and LV/LV lines.  A much smaller difference of 13 days was produced by the L to F polymorphism at 108 (FT/FT), demonstrating that both codon 108 and 189 polymorphisms can independently alter murine scrapie incubation times.

In order to assess the full effect of the polymorphisms in both the homozygous and heterozygous situation, LV/LV and FT/FT mice were crossed with wild type LT/LT mice, gene targeted FV/FV mice, and each other to produce the full repertoire of genetic combinations (Table I).  This breeding strategy produced 10 lines of transgenic mice, each with a different PrP allelic combination. Each line of mice was inoculated intracerebrally (i.c.) with ME7, and the resulting incubation times are shown in Table I and Figure S1.  

Introducing heterozygosity at codons 108 and 189 revealed that the control of incubation time by these two polymorphisms was not as straightforward as suggested by data in the homozygous lines (Table I).  There is no obvious pattern of allelic combination associated with increasing incubation time (Figure S1), with the exception that the two shortest incubation times are homozygous for 189T (155 days and 168 days), and the two longest are homozygous for 189V (295 days and 317 days) in keeping with identity at codon 189 with the source of the agent (LT/LT).  However, homozygosity at codon 189 does not always produce extreme incubation times, as LT/FT and LV/LV mice have intermediate incubation times of 196 and 261 days respectively (Table I).

An association between genotype and incubation time can be identified when the 10 lines are examined by the allelic combinations at either codon 108 or codon 189 (Table I).  When lines are sorted into groups by 189 genotype (189TT, 189VV, 189FV), the effect of codon 108 on incubation time is the same in each of the three groups: the  shortest incubation times occur when the codon at 108 is homozygous for either L or F although the shorter of the two is always 108LL, matching that of the source of the inoculum (LT/LT).  Therefore at codon 108, heterozygosity always leads to increased incubation times, with respect to the combination at codon 189, despite the inoculum matching with one allele at codon 108.  Indeed incubation times in excess of those in Prnpb (FV/FV) mice were observed in FV/LV mice (Table I and Figure S1).  However, when sorted by codon 108 genotype (108LL, 108FF, 108LF), a different pattern of incubation time is observed.  For each of the three groups homozygosity for threonine at codon 189 (which matches the source of the inoculum) gives shortest incubation times, homozygosity for valine (which does not match the inoculum) gives the longest incubation times, while the heterozygotes (TV) produce intermediate incubation times.  Hence, at codon 108 ME7 incubation times follow the pattern LL < FF < LF, while at codon 189 the pattern of incubation time is TT < TV < VV.  These results show that the effect on incubation period depends upon the combination of PrP alleles, particularly the presence of homozygosity or heterozygosity at codon 108 and codon 189 and on identity with the source of the inoculum at these positions in PrP.

Interactions between  codon 108 and 189 polymorphisms and the 301V strain.
In contrast to ME7 challenge, LT/LT mice inoculated with the Prnpb (FV/FV) passaged strain 301V have long incubation periods of 240 days. Similarly FV/FV mice which have long ME7 incubation periods produce short incubation periods of 125 days with 301V. The role of codon 108 and codon 189 in the control of 301V incubation time was explored by challenge of FT/FT and LV/LV mice.  Incubation times of 141 days and 202 days were obtained in LV/LV and FT/FT lines of mice respectively, compared to 125 days in FV/FV mice and 240 days in LT/LT mice (Table I).  Hence, in agreement with the data obtained from inoculations with ME7, both codon 108 and codon 189 are responsible for the control of incubation time for the 301V strain of agent.  Similar to ME7, the greatest effect was produced by the T to V alteration at codon 189 (~100 day reduction).  However the L to F change produced a greater effect on incubation time with 301V ( ~60 day reduction) than with ME7, again showing that challenge with an agent which shows identity at codon 108 or 189 results in shortest incubation times (Table I).  The full range of allelic combinations has not been examined with this strain of TSE agent.  In addition, no incubation time is available for the LT/FT line.  Six LT/FT mice were culled due to welfare reasons between 327 and 377 days, and all showed positive TSE pathology on examination of the brain tissue, suggesting an incubation time in excess of the LT/LT line (240 days). However, the combinations which were examined have produced patterns of incubation time alteration identical to those identified with ME7 (Table I and Figure S1), with the exception that the F1 cross LT/FV has an incubation time in excess of both parental lines.  This overdominance is characteristic of 301V, and can be observed with other TSE strains.  Thus the pattern of incubation time for 301V appears to be FF < LL < LF at codon 108, and VV < TV < TT at codon 189.  This pattern is the same as observed for ME7 where heterozygosity results in extended incubation times for 108LF, but intermediate incubation times with 189TV.  The shortest incubation times for both strains of agent reveal a  preference for identity with the genotype of the donor of infectivity (LT/LT for ME7 and FV/FV for 301V).

Effect of polymorphisms on PrPSc production.
Detergent homogenates were prepared from three terminal ME7 brains of each genotype.  The homogenates were treated with proteinase K and analysed by immunoblotting to assess the levels of PK-resistant PrP present in each model.  Equal levels of PK-resistant PrP were detected between the 3 mice of each genotype (data not shown).  The levels were also similar between the 10 different lines of mice (Figure 4), suggesting that the codon 108 and 189 polymorphisms have no effect on PrPSc levels in the brains of mice culled with clinical ME7 infection.  This was also true for the lines challenged with 301V (data not shown).

Effect of polymorphisms on vacuolar pathology.
The targeting of vacuolar pathology in the brain was similar for all allelic combinations infected with ME7 (Figure 5A-C.). Thus the codon 108 and codon 189 polymorphisms in host PrP do not influence the distribution of vacuolar pathology with the ME7 strain of scrapie. However, the polymorphisms appeared to affect the degree of vacuolation.  In general, lines containing 189TT (LT/LT, FT/FT, LT/FT), or 189TV with homozygosity at 108 (LT/LV, FT/FV) had short incubation times (<215 days) and gave very similar vacuolation profiles.  Lines displaying higher vacuolation scores had longer incubation times, and contained 189VV (FV/FV, LV/LV, FV/LV) or were heterozygous at both 108 and 189 (LV/FT). However, the LT/FV heterozygote gave a vacuolation profile more similar to LT/LT mice (Figure 5C).   Alternatively, these observations may simply reflect incubation time of disease, with high degrees of vacuolation being associated with extended incubation times.

The effect of the codon 108 and 189 polymorphisms on targeting was more prominent in 301V infected lines, where the targeting of vacuolation varied between LT/LT and FV/FV mice (Figure 5D-F).  189VV mice (LV/LV) and 189TV mice homozygous at 108 (LV/LT) gave profiles similar to FV/FV mice, while 189TT mice (FT/FT, LT/FT) gave profiles similar to LT/LT mice (Figure 5D-F). The LT/FV heterozygote produced an intermediate vacuolation profile (Figure 5F). The degree of vacuolation with 301V therefore does appear to be controlled by the codon 108 and codon 189 polymorphisms and not incubation time, as extended incubation times in FT/FT and LT/FT mice resulted in lower vacuolation scores in areas 7-9 compared to FV/FV mice (Figure 5A-B ).

Discussion
Previous experiments have shown that the introduction of 108F_189V into the murine Prnpa gene had a major effect on TSE disease, producing incubation times similar to those in Prnpb mice for both Sinc s7-derived (ME7, 139A, 79A, 301C) and Sinc p7-derived (301V, 22A) strains (Moore et al., 1998; Barron et al., 2003; Barron & Manson, 2004).  These results proved that amino acids 108 and 189 in murine PrP exert the major control over scrapie incubation time in Prnpa and Prnpb lines of mice, but could not determine whether either one or both of the polymorphisms were responsible for this control.  By targeting each polymorphism separately into the murine Prnpa gene we have been able to analyse the specific effect of codon 108 and 189 polymorphisms in co-isogenic mice, both independently and in several different allelic combinations.  Inoculation of these lines with two scrapie strains has shown that both codon 108 and 189 in murine PrP are responsible for control of scrapie incubation time in mice, as incubation times in LV/LV and FT/FT mice are distinct from those produced in LT/LT and FV/FV mice.  The shortest incubation times were obtained when PrP expressed from both alleles matched the PrP in the inoculum (LT/LT for ME7 and FV/FV for 301V).  Correspondingly, long incubation times were obtained for LT/LT mice with 301V and FV/FV mice with ME7.  However, from analysis of the other allelic combinations it was apparent that shortened incubation times were also obtained in lines where codon 189 matched the source of the inoculum and the residues on both alleles at codon 108 were homogeneous.  Of these, the shortest incubation times occurred when these residues at codon 108 matched the source of inoculum.  In lines heterozygous at both codon 108 and 189 (with LT and FV molecules in one case, and LV and FT molecules expressed in the other), the shorter incubation times were observed in the line expressing PrP which matched the source of inoculum (LT/LT for ME7).  The importance of homozygosity at codon 108 and identity with the inoculum at codon 189 suggests that these areas of the protein play very different roles in the disease process.   

The control of incubation-time is thought to be due to PrP sequence identity between the host and the donor of infectivity.  However our results show that short incubation times are obtained in FT/FT mice inoculated with LT/LT derived ME7, and LV/LV mice inoculated with FV/FV derived 301V, despite the sequence incompatibility between donor and host at codon 108.  Hence although codon 108 polymorphisms can independently affect scrapie incubation time, the major control is due to identity with the source of inoculum at codon 189.  The  inoculation of mice expressing different combinations of PrnpLT, PrnpFV, PrnpLV and PrnpFT produced a complex series of incubation times (Figure S1). It was clear that in addition to identity with the inoculum at codon 189, homozygosity at codon 108 consistently gave rise to shorter incubation times in both 108L/L and 108F/F expressing lines.  Heterozygosity at codon 108 always resulted in extended incubation times, with respect to the genotype at codon 189.  Although the series of allelic crosses produced for these experiments are described as homozygous and heterozygous at codons 108 and 189, expression from both Prnp alleles in a heterozygote will result in the presence of two different PrP populations in the cell.  It is interactions between these proteins and not between Prnp alleles which will determine the incubation time of disease.  Hence, the nature or combination of PrP variants in the recipient may be more important than PrP identity with the inoculum, indicating that interactions between amino acids 108 and 189, either on the same or different proteins, is a critical part of disease propagation. 

It has been proposed that the production of PrPSc is a two step process involving binding of PrP-res (Proteinase K resistant PrP) to PrP-sen (Proteinase K sensitive PrP) followed by the conversion of PrP-sen to PrP-res (Caughey, 2001).  However it is unknown which process requires PrP amino acid identity.  Cell free conversion experiments have shown that mouse PrP-res (108L_111V) will convert mouse PrP-sen expressing the 3F4 epitope (108M_111M), but not hamster PrP-sen (also possessing the 3F4 epitope), even though both proteins were found to bind to mouse PrP-res (Horiuchi et al., 2000).  Deletion mutants lacking residues 34-113 (MoPrP34-113) also bound to mouse PrP-res and converted, albeit with reduced efficiency (Lawson et al., 2001).  These results imply that amino acid 108 is not required for either initiation of conversion or binding to PrPSc, but may be involved in the control of the rate of conversion and final conformation of PrP-res (Lawson et al., 2004).  Moreover, MoPrP34-113 was found to bind heterologous PrPSc, but unlike the full length molecule, did not prevent the conversion of homologous PrPC, again suggesting this region is involved in the control of conversion, but not binding (Lawson et al., 2001).  The 34-113 truncation of PrPC was also found to affect the solubility of the molecule, as the loss of these residues reduced the percentage of PrP-sen which was seen to self aggregate when incubated under cell-free assay conditions in the absence of PrP-res.  This region may therefore be responsible for some degree of multimerisation/aggregation of PrP-sen which may be beneficial for conversion (Lawson et al., 2001).  

The individual effects of codon 108 and 189 polymorphisms in PrP have also been modelled in vitro by expressing recombinant 108F_189T and 108L_189V PrP in E. coli (Brown et al., 2000).  These intermediate forms of PrP were found to be less stable than both PrP-A (108L_189T) and PrP-B (108F_189V), and were observed to lose their normal conformation and gain some PK resistance over time.  It was proposed that inheritance of either 108F or 189V alone may be a disadvantage in terms of mouse survival, and that mice expressing either of these polymorphisms separately could potentially develop a spontaneous disease (Brown et al., 2000).  However, the recently reported existence of a Prnpc (108F_189T) expressing line (Lloyd et al., 2004), and the data presented here for transgenic FT/FT and LV/LV lines show that such mice are viable and do not develop any neurological phenotype during their lifespan.  PrP expressed in the brains of transgenic LT/LT and FV/FV mice is PK sensitive and expressed at levels identical to those in wild type mice of both genotypes.  These results clearly demonstrate that in vitro and in vivo studies can produce very different outcomes; these may be due to the difference in PrP post-translational modification, and the physiological environment of the native protein.  

From the data presented here, we predict that (i) polymorphisms at PrP codon 189 control the initial interaction and binding with the agent, as incubation times reflect a preference for sequence identity between the host and inoculum at codon 189; and (ii) polymorphisms at codon 108 control the rate of conversion of PrPC to PrPSc, where the ability to induce multimerisation of PrPC and increase the efficiency of conversion is favoured when all PrP expressed in a cell is homogeneous in the N-terminal region.  Alternatively, the preference for codon 108 homozygosity may reflect a more complex interaction between host PrPC and PrPSc which is less efficient in the presence of heterogeneous protein populations.  However, the importance of codon 108 homozygosity in murine scrapie transmission may explain the role of PrP codon 129 in human TSE disease, where the majority of CJD cases occur in individuals homozygous for methionine or valine at codon 129 (Palmer et al., 1991; Zeidler et al., 1997; Alperovitch et al., 1999).  There is an under-representation of M/V heterozygotes with CJD when compared to the distribution of genotypes in the normal population (Palmer et al., 1991), suggesting that a similar mechanism requiring N-terminal homogeneity controls the efficiency of disease transmission in humans.  

The results of transmissions to the 108L/F_189T/V lines of transgenic mice have therefore shown that codon 189 polymorphisms exert the major control over scrapie incubation time, but that the efficiency of disease transmission is increased when codon 108 is homozygous, suggesting that a multimer of PrPC may be involved in conversion of PrP during TSE disease. Several other studies have suggested the involvement of PrP dimers in disease (Priola et al., 1995; Warwicker, 1997; Meyer et al., 2000; Warwicker, 2000; Jansen et al., 2001; Meier et al., 2003), yet most existing dimer models do not consider dimerisation of the N-terminal region of PrP due to the lack of structural information available for this region.  Combined with the in vivo data produced in this study, the observations that amino acids 90-121 are retained after PK cleavage of PrPSc, and that deletion of this region affects susceptibility to disease (Fischer et al., 1996; Shmerling et al., 1998; Flechsig et al., 2000; Lawson et al., 2001; Supattapone et al., 2001), proves that this is a structurally important part of the molecule involved in the control of disease incubation time.  

Analysis of LV/LV and FT/FT transgenic mice has therefore shown that both amino acid polymorphisms at codons 108 and 189 in murine PrP are involved in the control of scrapie incubation time, and that distinct regions of PrP may play different roles in the disease process.  Interactions within a single PrP molecule and between molecules must therefore underlie the mechanism by which the incubation times are controlled. Such structural interactions may provide the key to replication of TSE infectivity.
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Figure 1.  Gene Targeting Strategy.   Wild type PrP clones were derived from a 129/Ola HM-1 ES cell genomic library, and amino acids modified by site directed mutagenesis.  Targeting vectors were constructed by the introduction of a PGK/HPRT cassette (flanked by LoxP sites) and a HSV/TK cassette for selection purposes.  After homologous recombination in ES cells, the PGK/HPRT cassette was removed with Cre recombinase.  Primer pair W262 and W6991 were used to determine successful homologous recombination in targeted ES cells.  Primer pair W7878 and W6991 were used to screen for the Cre-mediated deletion of  PGK-HPRT cassette (Materials and Methods).  In the presence of the cassette the PCR fragment is too large to amplify.  Successfully removed cassette produces a PCR product larger than the wild type allele due to the retention of a single LoxP site and part of the pBluescript multiple cloning site after Cre-recombination.   Presence of 108F or 189V polymorphism was confirmed by PCR of the ORF using primers A996 and B188 and digestion of the product with Mnl I (108F) and BstE II (189V).  B (Bam HI), E (Eco RI), P (Pst I), RV (Eco RV), S (Sal I).
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Figure 2. Northern blot of RNA extracted from mice expressing codon 108 and codon 189 polymorphisms.  
Lane 1, Prnpa;  Lane 2, PrP-/-;  Lane 3, PrnpLV/FT; Lane 4, PrnpFV/FV;  Lane 5, PrnpFV/-;  Lane 6, PrnpLT/LV;  Lane 7, PrnpLV/LV;  Lane 8, PrnpLT/FT;  Lane 9, PrnpFT/FT;  Lane 10, Prnpa. Top panel (a) probed with a 936bp Kpn I - Eco RI fragment from Prnp exon 3.  Bottom panel (b) probed with a PCR generated 275bp DNA fragment corresponding to the 18s rRNA sequence as a loading control.
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Figure 3. Western blot of uninfected mice expressing the codon 108 and codon 189 polymorphisms.  
Lane 1, wild type 129/Ola mouse (LT/LT); Lane 2, LV/LV mouse; Lane 3, FT/FT mouse; Lane 4 FV/FV mouse.  Top panel probed with anti PrP monoclonal antibody 7A12.  Bottom panel probed with anti-tubulin monoclonal antibody as a loading control.  
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Figure 4.  Western blot analysis of PrPSc levels in different allelic combinations inoculated with ME7.
Lanes 1-4 ME7 infected homozygous lines.  Lane 1,  LT/LT;  Lane 2, FV/FV; Lane 3, LV/LV;  Lane 4, FT/FT.
Lanes 5-10, ME7 infected heterozygous lines.  Lane 5, LT/FV;  Lane 6, LV/LT;  Lane 7, LV/FV;  Lane 8, FT/LT;  Lane 9, FT/FV;  Lane 10, FT/LV.
All samples treated with PK at 20µg/ml for 1 h at 370C.  Blot probed with anti-PrP monoclonal antibody 7A12.  Equivalent levels of PrPSc are present in all lines of mice.
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Figure 5.  Lesion Profiles of LV/LV and FT/FT transgenic mice infected with ME7 and 301V.
The extent of the vacuolar change in the brain was assessed semi-quantitatively in nine areas of grey matter and 3 areas of white matter by lesion profiling as described (Fraser & Dickinson, 1967).  Animals were scored on a scale of 0-5 in each specific area, and mean scores (calculated from a minimum of 6 animals) are shown graphically (error bars +/- SEM). Grey matter scoring areas: 1, dorsal medulla: 2, cerebellar cortex; 3, superior colliculus; 4, hypothalamus; 5, medial thalamus; 6, hippocampus; 7, septum; 8, cerebral cortex; 9, forebrain cerebral cortex.  White matter scoring areas: 1*, cerebellar white matter: 2*, midbrain white matter: 3*, cerebral peduncle. a, ME7 in lines with profiles similar to LT/LT mice; b. ME7 in lines with profiles similar to FV/FV mice; d, 301V in lines with profiles similar to LT/LT mice; e, 301V in lines with profiles similar to FV/FV mice; c & f, LT/LT. FV/FV and LT/FV lines with ME7 and 301V respectively.



		ME7 (LT/LT) 		301V (FV/FV)
Mouse Line	Prnp genotype	Incubation time (days) ± SEM	n*		Incubation time (days) ± SEM	n*
LT/LT	PrnpLT	155 ± 2	9		240 ± 6	14
FV/FV	PrnpFV	295 ± 7	10		125 ± 1	17
LV/LV	PrnpLV	261 ± 5	11		141	7
FT/FT	PrnpFT	168 ± 1	13		202 ± 1	13
LT/FV	PrnpLT/PrnpFV 	223 ± 4	6		269 ± 2	10
LT/LV	PrnpLT/PrnpLV 	191 ± 2	11		160 ± 2	27
LT/FT	PrnpLT/PrnpFT	196 ± 2	21		>300† 	6†
FV/LV	PrnpFV/PrnpLV	325 ± 7	9		N/A	N/A
FV/FT	PrnpFV/PrnpFT	215 ± 4	10		N/A	N/A
LV/FT	PrnpLV/PrnpFT	265 ± 3	12		N/A	N/A











Table I. Incubation times of ME7 and 301V in mice with different genetic combinations at codons 108 and 189.  
* Number of mice in each group.  All groups displayed 100% susceptibility.
† Six mice culled 327-377 days with intercurrent disease, all showing positive TSE pathology.
N/A – no data
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